Glycosaminoglycan mimetics inhibit SDF-1?CXCL12-mediated migration and invasion of human hepatoma cells

Glycobiology

Volumn 19, Issue 12, 2009, Pages 1511-1524

  Friand, Veronique ^a   Haddad, Oualid ^a   Papy Garcia, Dulce ^b   Hlawaty, Hanna ^a   Vassy, Roger ^a   Hamma Kourbali, Yamina ^b   Perret, Gerard Yves ^a   Courty, Jose ^b   Baleux, Françoise ^c   Oudar, Olivier ^a   Gattegno, Liliane ^a,d   Sutton, Angela ^a,d   Charnaux, Nathalie ^a,d  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c INSTITUT PASTEUR   (France)

^d HÔPITAL JEAN VERDIER   (France)

Author keywords

Chemokine; CXCL12; Glycosaminoglycan; Glycosaminoglycan mimetics; Hepatocellular carcinoma; SDF 1

Indexed keywords

ACETIC ACID; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; DEXTRAN; EXOSTOSIN 1; EXOSTOSIN 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARANASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; REGENERATING AGENT; STROMAL CELL DERIVED FACTOR 1; SULFATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSYNTHESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

BINDING, COMPETITIVE; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL COMMUNICATION; CELL MOVEMENT; CHEMOKINE CXCL12; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 71049123467     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp130     Document Type: Article

References (52)

1. Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot MA, Barritault D, Caruelle JP, Kern P. 2004. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J. 18:1147-1149.
2. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, Virelizier JL, Delepierre M, Baleux F, Lortat-Jacob H, et al. 1999. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 274:23916-23925.
3. Barbosa I, Morin C, Garcia S, Duchesnay A, Oudghir M, Jenniskens G, Miao HQ, Guimond S, Carpentier G, Cebrian J, et al. 2005. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J Cell Sci. 118:253-264.
4. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crepin M, Jozefonvicz J, Fermandjian S. 1999. Effects of the binding of a dextran derivative on fibroblast growth factor 2: Secondary structure and receptor binding studies. Biochem Pharmacol. 57:1399-1406.
5. Burger JA, Kipps TJ. 2006. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 107:1761-1767.
6. Charnaux N, Brule S, Hamon M, Chaigneau T, Saffar L, Prost C, Lievre N, Gattegno L. 2005. Syndecan-4 is a signaling molecule for stromal cell-derived factor-1 (SDF-1)/CXCL12. FEBS J. 272:1937-1951.
7. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest. 108:169-173.
8. Faber A, Roderburg C, Wein F, Saffrich R, Seckinger A, Horsch K, Diehlmann A, Wong D, Bridger G, Eckstein V, et al. 2007. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 3:26065-26075.
9. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A. 2001. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol. 167:4747-4757.
10. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, Vlodavsky I. 2003. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 17:1015-1025.
11. Gong F, Jemth P, Escobar Galvis ML, Vlodavsky I, Horner A, Lindahl U, Li JP. 2003. Processing of macromolecular heparin by heparanase. J Biol Chem. 278:35152-35158.
12. Goodger SJ, Robinson CJ, Murphy KJ, Gasiunas N, Harmer NJ, Blundell TL, Pye DA, Gallagher JT. 2008. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem. 283:13001-13008.
13. Götte M. 2003. Syndecans in inflammation. FASEB J. 17:575-591.
14. Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crepin M. 2001. Vascular endothelial growth factor 165 (VEGF165) activities are inhibited by carboxymethyl-benzylamide dextran that competes for heparin binding to VEGF165 and VEGF165-KDR complexes. J Biol Chem. 276:39748-39754.
15. Hamon M, Mbemba E, Charnaux N, Slimani H, Brule S, Saffar L, Vassy R, Prost C, Lievre N, Starzec A, et al. 2004. A syndecan-4/CXCR4 complex expressed on human primary lymphocytes and macrophages and HeLa cell line binds the CXC chemokine stromal cell-derived factor-1 (SDF-1). Glycobiology. 14:311-323.
16. Han J, Woytowich AE, Mandal AK, Hiebert LM. 2007. Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med. 232:927-934.
17. Handel TM, Johnson Z, Crown SE, Lau EK, Sweeney M, Proudfoot AE. 2005. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem. 74:385-410.
18. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. 2007. Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids? Clin Cancer Res. 13:1562-1570.
19. Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang X, Zheng X, Jiang H, Mikkelsen T, Chopp M. 2008. Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells. J Exp Clin Cancer Res. 27:23-31.
20. Ilan N, Elkin M, Vlodavsky I. 2006. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018-2039.
21. Johnson Z, Proudfoot AE, Handel TM. 2005. Interaction of chemokines and glycosaminoglycans: A new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 16:625-636.
22. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. 2005. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 24:4037-4051.
23. Kjellen L. 2003. Glucosaminyl N-desacetylase/N sulphotransferases in heparan sulphate biosynthesis and biology. Biochem Soc Trans. 31:340-342.
24. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, et al. 2005. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65:465-472.
25. Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D. 2006. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 281:37844-37852.
26. Lapierre F, Holme K, Lam L, Tressler RJ, Storm N, Wee J, Stack RJ, Castellot J, Tyrrell DJ. 1996. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6:355-366.
27. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP. 2000. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 275:29383-29390.
28. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N. 2008. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PloS One. 3:e2319.
29. Liotta LA, Kohn EC. 2001. The microenvironment of the tumour-host interface. Nature. 411:375-379.
30. Llovet JM, Beaugrand M. 2003. Hepatocellular carcinoma: Present status and future prospects. J Hepatol. 38(Suppl 1):S136-S149.
31. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C. 2001. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry. 40:6303-6318.
32. Meddahi A, Alexakis C, Papy D, Caruelle JP, Barritault D. 2002. Heparin-like polymer improved healing of gastric and colic ulceration. J Biomed Mater Res. 60:497-501.
33. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. 1996. New concepts in tissue repair: Skin as an example. Diabetes Metab. 22:274-278.
34. Merry CL, Lyon M, Deakin JA, Hopwood JJ, Gallagher JT. 1999. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem. 274:18455-18462.
35. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E. 2007. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem. 282:10018-10027.
36. Murphy KJ, Merry CL, Lyon M, Thompson JE, Roberts IS, Gallagher JT. 2004. A new model for the domain structure of heparan sulfate based on the novel speci.city of K5 lyase. J Biol Chem. 279:27239-27245.
37. Papy-Garcia D, Barbier-Chassefie V, Rouet V, Kerros ME, Klochendler C, Tournaire MC, Barritault D, Caruelle JP, Petit E. 2005. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules. 38:4647-4654.
38. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. 1999. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59:3433-3441.
39. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. 2006. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem. 281:1731-1740.
40. Rossi D, Zlotnik A. 2000. The biology of chemokines and their receptors. Annu Rev Immunol. 18:217-242.
41. Rouet V, Meddahi-Pelle A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D. 2006. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res A78:792-797.
42. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. 2004. Heparan sulfate/ heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/ CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem. 279:43854-43860.
43. Salmivirta M, Lidholt K, Lindahl U. 1996. Heparan sulfate: A piece of information. FASEB J. 10:1270-1279.
44. Schimanski CC, Bahre R, Gockel I, Muller A, Frerichs K, Horner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, et al. 2006. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer. 95:210-217.
45. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, Alon R, Lider O. 2004. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol. 172:5185-5193.
46. Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poire A, Saffar L, Kraemer M, Vassy J, et al. 2007. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res. 5:21-33.
47. Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, et al. 2007. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther. 6:2948-2958.
48. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M. 2005. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 146:333-343.
49. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N. 2003. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 550:79-83.
50. Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J. 1999. Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate. 38:126-136.
51. Van Den Born J, Gunnarsson K, Bakker MA, Kjellen L, Kusche-Gullberg M, Maccarana M, Berden JH, Lindahl U. 1995. Presence of N unsubstituted glucosamine units in native heparan sulfate revealed by monoclonal antibody. J Biol Chem. 270:31303-31309.
52. Wegrowski Y, Milard AL, Kotlarz G, Toulmonde E, Maquart FX, Bernard J. 2006. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin Exp Immunol 144:485-493.